FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Ranitidine Injection, USP
Status: Discontinuation
»Therapeutic Categories: Gastroenterology

Expand all

Mylan Institutional (Revised 04/03/2020)

Company Contact Information:
800-796-9526

Presentation Posting Date Related Information
Ranitidine Injection 25 mg/mL, 2ml vial; 10 pack; (NDC 67457-397-99) 04/03/2020
FDA Requests Removal of All Ranitidine Products (Zantac) from the Market
Ranitidine Injection 25 mg/mL, 6 mL vial; 1 pack; (NDC 67457-398-62) 04/03/2020
FDA Requests Removal of All Ranitidine Products (Zantac) from the Market

Teligent Pharma, Inc. (Revised 04/03/2020)

Company Contact Information:
856-697-1441

Presentation Posting Date Related Information
ZANTAC INJECTABLE 25MG/ML 2ML VIAL (NDC 52565-101-01) 04/03/2020
FDA Requests Removal of All Ranitidine Products (Zantac) from the Market
ZANTAC INJECTABLE 25MG/ML 40ML VIAL (NDC 52565-096-01) 04/03/2020
FDA Requests Removal of All Ranitidine Products (Zantac) from the Market
ZANTAC INJECTABLE 25MG/ML 6ML VIAL (NDC 52565-102-01) 04/03/2020
FDA Requests Removal of All Ranitidine Products (Zantac) from the Market

Zydus Pharmaceuticals USA Inc. (Revised 04/03/2020)

Company Contact Information:
609-730-1900

Presentation Posting Date Related Information
Ranitidine HCl Injection 25mg/mL (10x2mL SD vials)(NDC 68382-422-02) 04/03/2020
FDA Requests Removal of All Ranitidine Products (Zantac) from the Market
Ranitidine HCl Injection 25mg/mL (6mL MD vial)(NDC 68382-423-06) 04/03/2020
FDA Requests Removal of All Ranitidine Products (Zantac) from the Market

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English